Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation


In patients with atrial fibrillation (AF), anticoagulation reduces the risk of stroke and embolic events and improves survival. Annually, nearly 250 000 AF patients in the United States alone require temporary interruption (TI) of anticoagulation for invasive procedures, acute illness, or bleeding events. Bridging therapy may or may not be pursued on Background—During long-term anticoagulation in atrial fibrillation, temporary interruptions (TIs) of therapy are common, but the relationship between patient outcomes and TIs has not been well studied. We sought to determine reasons for TI, the characteristics of patients undergoing TI, and the relationship between anticoagulant and outcomes among patients with TI. Methods and Results—In the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), a randomized, double-blind, double-dummy study of rivaroxaban and warfarin in nonvalvular atrial fibrillation, baseline characteristics, management, and outcomes, including stroke, non–central nervous system systemic embolism, death, myocardial infarction, and bleeding, were reported in participants who experienced TI (3–30 days) for any reason. The at-risk period for outcomes associated with TI was from TI start to 30 days after resumption of study drug. In 14 236 participants who received at least 1 dose of study drug, 4692 (33%) experienced TI. Participants with TI were similar to the overall ROCKET AF population in regard to baseline clinical characteristics. Only 6% (n=483) of TI incidences involved bridging therapy. Stroke/systemic embolism rates during the at-risk period were similar in rivaroxaban-treated and warfarin-treated participants (0.30% versus 0.41% per 30 days; hazard ratio [confidence interval]=0.74 [0.36–1.50]; P=0.40). Risk of major bleeding during the at-risk period was also similar in rivaroxaban-treated and warfarintreated participants (0.99% versus 0.79% per 30 days; hazard ratio [confidence interval]=1.26 [0.80–2.00]; P=0.32). Conclusions—TI of oral anticoagulation is common and is associated with substantial stroke risks and bleeding risks that were similar among patients treated with rivaroxaban or warfarin. Further investigation is needed to determine the optimal management strategy in patients with atrial fibrillation requiring TI of anticoagulation. Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00403767. (Circulation. 2014;129:1850-1859.)

9 Figures and Tables

Citations per Year

128 Citations

Semantic Scholar estimates that this publication has 128 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Sherwood2014OutcomesOT, title={Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation}, author={W . A . Sherwood and James Demetrios Douketis and Rachna Patel and Jonathan P Piccini and Anne S . Hellkamp and Yuliya V Lokhnygina and Alex C . Spyropoulos and Graeme J. Hankey and Daniel Singer and Christopher C . Nessel and Wendy Mahaffey and Amanda A. Fox and Robert M. Califf and Richard C. Becker}, year={2014} }